Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Based on UOB Kay Hian (UOBKH) Research, the next few quarters should continue to see decent growth, on the back of increased patient volume from China following the launch of the sales representative office (SRO); the commencement of an additional satellite clinic in Jakarta, Indonesia; the launch of its inaugural in-vitro fertilisation (IVF) facility in the Philippines; and the maturing of the newly-launched Alhaya Fertility Centre
Alpha IVF 2Q net profit up 24% driven by foreign patients, revenue increased 12.2% year-on-year to RM43.24 million, from RM38.54 million in 2QFY2024, according to the fertility care specialist's bourse filing.